Table 2.
The Clinical Parameters, Immunohistochemistry and Molecular Findings of 15 non-E-GMB and E-GMB Patients
| Non-E-GMB (n=15) | E-GMB (n=15) | p | ||
|---|---|---|---|---|
| Gender | 1.000 | |||
| Female | 4 | 3 | ||
| Male | 11 | 12 | ||
| Median Age (years) | 63 | 34 | 0.002 | |
| EZH2 Overexpression | 7 | 8 | 0.713 | |
| 8 | 7 | |||
| MGMT | 0.715 | |||
| No methylation | 7 | 8 | ||
| Methylation | 8 | 7 | ||
| BRAFV600E | 0.010 | |||
| WT | 15 | 8 | ||
| Mutation | 0 | 7 | ||
| 1p_19qFISH | ||||
| No deletion | 14 | 15 | 1.000 | |
| Deletion | 1 | 0 | ||
| IDH 1 | 1.000 | |||
| WT | 14 | 15 | ||
| Mutation | 1 | 0 | ||
| Median OS | 20.000±3.212 | 8.000±2.404 | 0.079 | |
Abbreviations: E-GBM, epithelioid glioblastoma; EZH2, enhancer of zeste 2; MGMT, O-6-methylguanine-DNA methyltransferase; BRAF, v-raf murine sarcoma viral oncogene homolog B1; FISH, fluorescence in situ hybridization; IDH1, isocitrate dehydrogenase1; WT, wild type; OS, overall survival.